Tatum Toland, APRN
Family · Topeka, KSNPI 1376068908
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $87,943 of the $108,301 with a category attached, or 81.2%. AbbVie accounts for 98.4% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2024 at $47,455 and has fallen 59.2% since, to $19,369 in 2025. Among family clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 350 payments — averaging $309.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$107K
- Galderma Laboratories, L.p.$262
- Johnson & Johnson$257
- Lilly USA, LLC$234
- Sanofi$219
- LEO Pharma Inc.$199
- plus $580 from 14 others
What the payments were for
- Consulting fees$6701%
- Speaking & faculty fees$87,94381%
- Travel & lodging$11,62211%
- Food & beverage$7,8087%
- Education$2590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 276 | $106,551 |
| Galderma Laboratories, L.p. | 9 | $262 |
| Johnson & Johnson | 6 | $257 |
| Lilly USA, LLC | 19 | $234 |
| Sanofi | 7 | $219 |
| LEO Pharma Inc. | 5 | $199 |
| E.r. Squibb & Sons, L.L.C. | 7 | $147 |
| Amgen | 3 | $130 |
| Arcutis Biotherapeutics, Inc. | 3 | $50 |
| Regeneron Healthcare Solutions, Inc. | 2 | $47 |
| Sun Pharmaceutical Industries Inc. | 2 | $29 |
| Pfizer | 2 | $29 |
| VYNE Pharmaceuticals Inc. | 2 | $29 |
| Novartis | 1 | $23 |
| Almirall LLC | 1 | $18 |
| Incyte Corporation | 1 | $17 |
| Verrica Pharmaceuticals Inc. | 1 | $17 |
| Organogenesis Inc. | 1 | $15 |
| UCB, Inc. | 1 | $14 |
| Tactile Systems Technology Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$108,301 in reported general payments places this provider in the 95th percentile of 1,579 family providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 15 | $102,173 |
| Dupixent PenDupilumab | 21 | $76,775 |
| Taltz AutoinjectorIxekizumab | 11 | $73,943 |
| Clobetasol Propionate | 26 | $2,778 |
| Ketoconazole | 52 | $943 |
| Halobetasol Propionate | 18 | $680 |
| Triamcinolone Acetonide | 28 | $397 |
Paid to pharmacies, not to this prescriber.
Other family in Topeka
- Ansley McKennaTopeka$8K
- Jason CrenshawTopeka$7K
- Zohra HussainiKansas City$329K
- Jennifer ChesterOverland Park$327K
- Amanda CaldwellLeawood$203K
- Kayla del RioWichita$147K
- Kelli RiceWichita$114K
- Mary GonzalesWichita$87K
- Erin FeitzOverland Park$36K
- Adam CaseKansas City$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.